However, our results show that the low expression of RBBP5 and BCL9 is related to a better prognosis of breast cancer, which indicates that the abnormal Wnt pathway may also be inhibited by reducing the expression of RBBP5 and BCL9 in breast cancer, thus achieving better targeted therapy. This evidence concerns the gene BCL9 and breast carcinoma.